Table 2 Baseline characteristics of enrolled TIA participants.
From: Validation of CSR model to predict stroke risk after transient ischemic attack
All TIA patients (n = 1186) | TIA patients with negative DWI (n = 712) | TIA patients with positive DWI (n = 474) | P value | |
|---|---|---|---|---|
Age ≥ 60 | 531 (44.8%) | 312 (43.8%) | 219 (46.2%) | 0.419 |
Male | 719 (60.6%) | 409 (57.4%) | 310 (65.4%) | 0.006 |
Current smoking | 335 (28.3%) | 170 (23.9%) | 165 (35.0%) | < 0.001 |
DWI in 3 days | 953 (80.4%) | 562 (78.9%) | 391 (82.5%) | 0.131 |
Medical history | ||||
Hypertension | 650 (54.8%) | 370 (52.0%) | 280 (59.1%) | 0.016 |
Diabetes | 207 (17.5%) | 113 (15.9%) | 94 (19.8%) | 0.078 |
Dyslipidemia | 227 (19.1%) | 129 (18.1%) | 98 (20.7%) | 0.273 |
Coronary heart disease | 154 (13.0%) | 95 (13.3%) | 59 (12.4%) | 0.653 |
Atrial fibrillation | 26 (2.2%) | 11 (1.5%) | 15 (3.2%) | 0.062 |
History of stroke | 248 (20.9%) | 136 (19.1%) | 112 (23.6%) | 0.060 |
ABCD3-I score (median, IQR) | 5 (4–7) | 5 (4–7) | 7 (6–9) | < 0.001 |
CSR score (median, IQR) | 1 (0–2) | 1 (0–2) | 4 (1–6) | < 0.001 |
Discharge treatment | ||||
Antiplatelet agents | 1116 (94.1%) | 664 (93.3%) | 452 (95.4%) | 0.133 |
Anticoagulant | 38 (3.2%) | 13 (1.8%) | 25 (5.3%) | 0.001 |
Lipid-lowering agents | 1108 (93.4%) | 660 (92.7%) | 448 (94.5%) | 0.216 |
Antihypertension agents | 398 (33.6%) | 239 (33.6%) | 159 (33.5%) | 0.993 |
Hypoglycemic agents | 230 (19.4%) | 126 (17.7%) | 104 (21.9%) | 0.070 |
